Phaseline

Companies › Aragon Pharmaceuticals

Aragon Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 29 registered trials: 15 Phase 2, 12 Phase 3, 2 Phase 1; Oncology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Apalutamide (ARN-509)
Androgen Receptor antagonist
ARPhase 3Prostatic Neoplasms; Prostate Cancer; Prostatic Neoplasms, Castration-Resistant; Androgen Axis Suppression …Mar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06758882Apalutamide (ARN-509)Phase 2High Risk Prostate CancerOncologyJan 2026
NCT06067269Apalutamide (ARN-509)Phase 2Prostate AdenocarcinomaOncologyDec 2026
NCT05406999Apalutamide (ARN-509)Phase 2Neoadjuvant TherapyOncologyDec 2026
NCT03902951Apalutamide (ARN-509)Phase 2Metastatic Prostate AdenocarcinomaOncologyJan 2027
NCT03436654Apalutamide (ARN-509)Phase 2Prostate CancerOncologyFeb 2027
NCT02531516Apalutamide (ARN-509)Phase 3Prostatic NeoplasmsOncologyMar 2027
NCT04812366Apalutamide (ARN-509)Phase 2Prostate CancerOncologyJun 2027
NCT02949284Apalutamide (ARN-509)Phase 2Stage II Prostate AdenocarcinomaOncologyJun 2027
NCT06274047Apalutamide (ARN-509)Phase 3Androgen Axis SuppressionOncologyJun 2027
NCT07260435Apalutamide (ARN-509)Phase 3Prostate CancerOncologyNov 2027
NCT01946204Apalutamide (ARN-509)Phase 3Prostatic NeoplasmsOncologyDec 2027
NCT02257736Apalutamide (ARN-509)Phase 3Prostatic NeoplasmsOncologyDec 2027
NCT02489318Apalutamide (ARN-509)Phase 3Prostate CancerOncologyDec 2027
NCT02123758Apalutamide (ARN-509)Phase 1Prostatic NeoplasmsOncologyDec 2027
NCT02592317Apalutamide (ARN-509)Phase 1Prostatic Neoplasms, Castration-ResistantOncologyDec 2027
NCT06832774Apalutamide (ARN-509)Phase 2Prostate Cancer Metastatic DiseaseOncologyDec 2027
NCT04267887Apalutamide (ARN-509)Phase 2Castration-Sensitive Prostate CarcinomaOncologyJan 2028
NCT03412396Apalutamide (ARN-509)Phase 2Prostate AdenocarcinomaOncologyMar 2028
NCT02703623Apalutamide (ARN-509)Phase 2Castration Levels of TestosteroneOncologyMar 2028
NCT04181203Apalutamide (ARN-509)Phase 3Prostate CancerOncologySep 2028
NCT03821792Apalutamide (ARN-509)Phase 2Metastatic Prostate CarcinomaOncologyOct 2028
NCT04295447Apalutamide (ARN-509)Phase 2Prostatic NeoplasmsOncologyNov 2028
NCT07751133Apalutamide (ARN-509)Phase 3Prostate CancerOncologyAug 2029
NCT05191680Apalutamide (ARN-509)Phase 2Prostate CancerOncologyOct 2029
NCT03371719Apalutamide (ARN-509)Phase 2Recurrent Prostate CarcinomaOncologyMar 2030
NCT07333066Apalutamide (ARN-509)Phase 3Metastatic Hormone-sensitive Prostate CancerOncologyMar 2030
NCT04134260Apalutamide (ARN-509)Phase 3Prostate AdenocarcinomaOncologyNov 2031
NCT04423211Apalutamide (ARN-509)Phase 3Biochemically Recurrent Prostate CarcinomaOncologyDec 2032
NCT04513717Apalutamide (ARN-509)Phase 3Prostate AdenocarcinomaOncologyDec 2033

Targets

AR (1)

Companies with the same targets

Johnson & Johnson (Janssen) Novartis Astellas Alessa Therapeutics Sun Pharmaceutical Industries Hansoh BioMedical R&D Company Merck & Co. (MSD) Bayer Qilu Pharmaceutical AstraZeneca

Companies built like this

Tolmar Amneal Pharmaceuticals LaNova Medicines Zhejiang Quetzal Therapeutics Beijing Pearl Biotechnology Limited Liability Company

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.